Last updated: August 31, 2026
Empagliflozin has a stronger commercial trajectory than linagliptin. Jardiance has become a major growth product in type 2 diabetes, heart failure, and chronic kidney disease, while Tradjenta has entered a mature-to-declining phase because DPP-4 inhibitors face lower pricing, generic competition, and displacement by SGLT2 and GLP-1 therapies. The fixed-dose combination Glyxambi links the two ingredients but remains a smaller commercial asset.
Empagliflozin has broader clinical demand, stronger guideline support, and greater non-diabetes revenue potential. Linagliptin retains value in patients requiring a weight-neutral, low-hypoglycemia oral therapy, particularly those with renal impairment, but its market position is more vulnerable to class substitution.
What are empagliflozin and linagliptin, and how do they compete?
Empagliflozin is an SGLT2 inhibitor marketed primarily as Jardiance by Boehringer Ingelheim and Eli Lilly. Linagliptin is a DPP-4 inhibitor marketed primarily as Tradjenta by Boehringer Ingelheim and Eli Lilly.
| Product |
Active ingredient |
Primary class |
Principal brands |
Main commercial markets |
| Jardiance |
Empagliflozin |
SGLT2 inhibitor |
Jardiance, Synjardy, Glyxambi |
Type 2 diabetes, heart failure, chronic kidney disease |
| Tradjenta |
Linagliptin |
DPP-4 inhibitor |
Tradjenta, Jentadueto, Glyxambi |
Type 2 diabetes |
| Glyxambi |
Empagliflozin plus linagliptin |
SGLT2/DPP-4 combination |
Glyxambi |
Type 2 diabetes |
| Synjardy |
Empagliflozin plus metformin |
SGLT2/metformin combination |
Synjardy, Synjardy XR |
Type 2 diabetes |
Empagliflozin reduces renal glucose reabsorption and has demonstrated cardiovascular and renal benefits beyond glucose lowering. Linagliptin increases endogenous incretin activity and lowers glucose without the weight gain and hypoglycemia profile associated with sulfonylureas or insulin.
The competitive distinction is important. Empagliflozin competes across diabetes, heart failure, and kidney disease. Linagliptin competes mainly within the diabetes market and against other DPP-4 inhibitors such as sitagliptin, saxagliptin, and alogliptin.
How large is the empagliflozin and linagliptin market?
Empagliflozin is the larger and faster-growing asset. Jardiance has become one of the leading products in the SGLT2 category, supported by cardiovascular and renal indications. The global SGLT2 market has expanded through increased use in patients without diabetes, particularly in heart failure and chronic kidney disease.
Lilly reported Jardiance revenue of approximately $7.1 billion in 2023, up from approximately $5.8 billion in 2022. Jardiance revenue continued to grow in 2024, although the reported figure depends on Lilly’s geographic and alliance accounting presentation [1].
Tradjenta is materially smaller. Boehringer Ingelheim and Lilly do not disclose a separate, current global Tradjenta revenue line with the same level of detail as Lilly reports for Jardiance. Public company reporting places Tradjenta in a mature product group rather than among the companies’ principal growth drivers [1][2].
Commercial scale comparison
| Metric |
Empagliflozin/Jardiance |
Linagliptin/Tradjenta |
| Commercial phase |
Growth to late-growth |
Mature to declining |
| Core therapeutic market |
Diabetes, heart failure, CKD |
Type 2 diabetes |
| Major clinical expansion |
Strong |
Limited |
| Pricing power |
Relatively strong before broad generic entry |
Eroding |
| Generic substitution risk |
Emerging and substantial |
High |
| GLP-1 competition |
Indirect |
Direct treatment-algorithm pressure |
| Renal differentiation |
Strong |
Dosing convenience, not disease-modifying benefit |
| Strategic value |
High |
Defensive and combination-oriented |
The combined empagliflozin and linagliptin market is therefore asymmetric. Most future value is concentrated in empagliflozin, while linagliptin contributes formulation breadth and a residual oral-diabetes franchise.
What is driving empagliflozin growth?
Cardiovascular and heart-failure indications
The EMPEROR-Reduced and EMPEROR-Preserved trials supported empagliflozin use in heart failure with reduced and preserved ejection fraction. The FDA approved Jardiance for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, including patients without diabetes [3].
These indications expand the prescriber base beyond endocrinologists. Cardiologists, nephrologists, and primary-care physicians increasingly influence SGLT2 prescribing.
Chronic kidney disease
The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death in a broad chronic kidney disease population, including patients without diabetes [4]. The FDA later expanded Jardiance’s labeling to include adults with chronic kidney disease at risk of progression.
This indication increases the addressable population and reduces dependence on glycated hemoglobin control as the principal prescribing rationale.
Guideline adoption
The American Diabetes Association, European Association for the Study of Diabetes, American Heart Association, and kidney-disease organizations have incorporated SGLT2 inhibitors into treatment pathways for patients with cardiovascular, heart-failure, or renal risk. Guideline positioning supports continued use even when competing glucose-lowering therapies provide greater weight loss.
Combination with GLP-1 therapies
Empagliflozin may be used with GLP-1 receptor agonists rather than replaced by them. The combination can address separate clinical objectives: SGLT2 inhibitors for heart-failure and renal risk, and GLP-1 therapies for weight reduction and atherosclerotic cardiovascular risk.
The principal limit is cost. Commercial payers may require step therapy, prior authorization, or evidence of inadequate response to lower-cost drugs.
Why is linagliptin losing relative market share?
Linagliptin’s principal strengths are renal dosing simplicity, oral administration, low hypoglycemia risk, and weight neutrality. Unlike several competitors, linagliptin generally does not require dose adjustment across degrees of renal impairment.
Its weaknesses are commercial rather than safety-driven. DPP-4 inhibitors have modest glucose-lowering efficacy, limited weight benefit, and less compelling heart-failure or kidney-disease outcomes than SGLT2 inhibitors. They also face direct competition from low-cost metformin, sulfonylureas, insulin, generic DPP-4 products, GLP-1 receptor agonists, and SGLT2 inhibitors.
Linagliptin remains relevant in several segments:
- Older patients for whom hypoglycemia avoidance is important.
- Patients who cannot tolerate GLP-1 therapy.
- Patients for whom weight loss is not a treatment objective.
- Patients with renal impairment who benefit from a simple dosing regimen.
- Patients seeking an oral therapy without the genital and urinary adverse effects associated with SGLT2 inhibitors.
The drug’s market is likely to contract gradually rather than disappear. The largest risk is formulary exclusion or unfavorable tier placement, not a sudden loss of clinical utility.
What patents protect empagliflozin, linagliptin, and Glyxambi?
The patent estate includes active-ingredient patents, solid-state or crystalline-form patents, formulation patents, combination patents, and method-of-use patents. The commercial risk differs by product.
Empagliflozin patent estate
Jardiance protection has historically relied on:
- Core chemical-compound patents covering empagliflozin and related C-glucoside derivatives.
- Pharmaceutical-composition patents.
- Combination patents covering empagliflozin with metformin or linagliptin.
- Method-of-use patents covering diabetes, cardiovascular, and renal indications.
- Regulatory exclusivity and pediatric extensions.
The core U.S. compound protection for empagliflozin has reached or approached its effective patent term in the mid-2020s, subject to patent-term adjustment, pediatric exclusivity, and the specific Orange Book listing at issue. Later patents may create narrower protection for formulations, combinations, or particular uses.
The commercial significance is that an ANDA applicant may challenge the principal compound patent while accepting or carving out certain method-of-use indications. A generic could therefore enter with a diabetes label while remaining subject to litigation over heart-failure or kidney-disease uses.
Linagliptin patent estate
Linagliptin protection has included:
- Compound patents for xanthine-based DPP-4 inhibitors.
- Process and intermediate patents.
- Solid-state or polymorph patents.
- Formulation patents.
- Combination patents with metformin and empagliflozin.
- Method-of-use patents for glycemic control.
The key effective protection period for branded linagliptin has been later than some older DPP-4 products because of patent-term adjustments, pediatric exclusivity, and formulation or combination patents. The practical entry date depends on which Orange Book patents an ANDA applicant challenges and whether settlements delay launch.
Glyxambi protection
Glyxambi combines empagliflozin and linagliptin in a single tablet. Its protection is more vulnerable than Jardiance’s disease-area franchise because:
- Generic applicants can target the individual components separately.
- A patient can receive the same ingredients as separate tablets.
- Combination-product patents may not prevent substitution with component products.
- The fixed-dose product has a narrower addressable market than the individual ingredients.
The main commercial value of Glyxambi is convenience and adherence. Its patent value is lower if payers favor separate generic components or if generic empagliflozin becomes available.
When do empagliflozin and linagliptin lose exclusivity?
There is no single global loss-of-exclusivity date because patent protection varies by jurisdiction, product, patent family, pediatric extension, and settlement agreement.
| Product |
U.S. exclusivity outlook |
Principal risk |
| Jardiance |
Core protection reaches the mid-2020s; later listed patents may extend narrower protection |
ANDA challenges and authorized generic entry |
| Tradjenta |
Core and formulation protection extend into the mid-to-late 2020s depending on patent and settlement posture |
Generic DPP-4 substitution |
| Glyxambi |
Combination protection may extend beyond some component patents |
Separate-tablet substitution and narrow commercial uptake |
| Synjardy |
Combination and formulation protection varies by strength and product version |
Generic empagliflozin plus metformin |
The effective loss of exclusivity may precede the final patent expiration if a generic launches under a settlement license, an authorized generic is introduced, or payers force net-price reductions before legal exclusivity ends.
What is the FDA and Orange Book status of these products?
Jardiance, Tradjenta, Glyxambi, and Synjardy are FDA-approved prescription products. Their approved indications are listed in FDA labeling and reflected through Orange Book product and patent records [3][5].
The Orange Book is central to U.S. generic-entry analysis because listed patents can trigger a 30-month stay when challenged through a Paragraph IV certification. The stay does not guarantee patent validity. It delays FDA approval while infringement litigation proceeds, subject to statutory exceptions.
Relevant regulatory pathways include:
- ANDA approval for chemically equivalent generic tablets.
- Paragraph IV certification against listed patents.
- Section viii statements that omit protected uses where appropriate.
- New drug applications for products with labeling or formulation differences.
- Patent-listing disputes if an applicant argues that a listed patent does not properly claim the approved product.
For empagliflozin, a section viii strategy could permit diabetes-market entry while excluding certain heart-failure or kidney-disease uses. The enforceability of that approach depends on the label, the claims, and the prescribing behavior that follows generic launch.
Which companies are challenging empagliflozin and linagliptin?
Generic manufacturers with large ANDA portfolios are the most likely challengers. The relevant competitive set includes Teva, Sandoz, Lupin, Zydus, Sun Pharma, Dr. Reddy’s, Cipla, Torrent, and other manufacturers active in U.S. diabetes products.
The commercial challenge may come through several routes:
- Paragraph IV litigation against core or formulation patents.
- Paragraph III filings awaiting patent expiration.
- Authorized generic arrangements.
- Market entry outside the United States before U.S. launch.
- Separate-component competition against fixed-dose combinations.
- Biosimilar-style price pressure is not applicable because these are small-molecule drugs, but generic substitution is.
A biosimilar risk analysis is therefore not appropriate for empagliflozin or linagliptin. Both are chemically synthesized small molecules and face ANDA generic competition, not the abbreviated biologics pathway under the Public Health Service Act.
What patent litigation and settlement risks affect the franchise?
The most important litigation issues are likely to involve:
- Validity of compound patents.
- Obviousness challenges based on earlier SGLT2 or DPP-4 chemistry.
- Infringement of crystalline-form and formulation patents.
- Scope of method-of-use claims.
- Whether an ANDA label induces infringement.
- Whether a generic can omit heart-failure or kidney-disease language.
- Settlement dates and restrictions on authorized generic competition.
A settlement can preserve significant value even after the core patent has been challenged. Branded companies may grant a future launch date, allow an authorized generic, or settle without admitting validity or infringement. The financial impact depends on the number of entrants and the agreed launch date.
For Jardiance, litigation has greater economic importance because the underlying product has multi-billion-dollar annual sales. For Tradjenta, litigation economics are more constrained. A later launch may preserve some revenue, but declining DPP-4 utilization limits the value of prolonged exclusivity.
How does the financial trajectory compare between the two ingredients?
Empagliflozin
Empagliflozin’s trajectory has three phases:
- Expansion phase: Growth in type 2 diabetes and increasing share within the SGLT2 class.
- Indication-expansion phase: Uptake in heart failure and chronic kidney disease, including non-diabetic patients.
- Post-exclusivity phase: Price compression after generic entry, moderated by brand loyalty, combination products, and differentiated cardiovascular and renal labeling.
Jardiance is likely to remain economically important after generic entry, but branded revenue can fall rapidly once several generic manufacturers receive approval. The timing and depth of erosion will depend on the number of entrants, payer substitution, authorized generic policy, and whether combination products receive separate commercial protection.
Linagliptin
Linagliptin’s trajectory is more mature:
- Initial adoption: Use as a renal-friendly oral DPP-4 inhibitor.
- Combination expansion: Glyxambi and Jentadueto broadened prescribing options.
- Mature-franchise phase: Lower growth as SGLT2 and GLP-1 therapies gain preference.
- Generic erosion: Rapid price and volume pressure after broad substitution.
The residual value of Tradjenta will depend on access in renal populations, the persistence of DPP-4 use in older patients, and the relative cost of newer branded alternatives.
What generic launch scenarios exist for empagliflozin and linagliptin?
| Scenario |
Empagliflozin impact |
Linagliptin impact |
| Single generic entrant |
Moderate price erosion; brand may retain preferred access |
Significant erosion because class demand is mature |
| Multiple simultaneous entrants |
Rapid price decline and formulary substitution |
Severe revenue compression |
| Authorized generic only |
Managed erosion and possible channel preservation |
Limited protection if independent generics follow |
| Diabetes-only label |
Early volume pressure in diabetes |
Broad substitution across principal indication |
| Delayed heart-failure or CKD labels |
Brand retains some specialty use |
Not relevant to most linagliptin demand |
| Combination-product competition |
Pressure on Glyxambi and Synjardy |
Pressure on Glyxambi and Jentadueto |
Empagliflozin is more likely to retain a meaningful branded base because the drug has disease-area utility beyond diabetes. Linagliptin has fewer clinical barriers to substitution because most of its value is tied to glycemic control.
How strong is the patent estate and commercial position?
Empagliflozin has the stronger commercial estate, even as core patent life declines. Its strength comes from clinical evidence, multiple indications, specialist adoption, and a broad product family.
Linagliptin has a technically meaningful patent estate but a weaker commercial position. Patent protection can delay generic entry, but it cannot fully offset therapeutic substitution by SGLT2 inhibitors and GLP-1 therapies.
| Factor |
Empagliflozin |
Linagliptin |
| Indication breadth |
High |
Low to moderate |
| Clinical differentiation |
High |
Moderate |
| Revenue concentration |
High-value growth brand |
Mature product |
| Patent litigation value |
High |
Moderate |
| Generic vulnerability |
High after entry |
Very high after entry |
| Combination-product relevance |
Moderate |
Moderate |
| Long-term franchise value |
Stronger |
Defensive |
What geographic markets matter most?
The United States remains the most important profit pool because of product pricing and the size of the branded diabetes, heart-failure, and kidney-disease markets. Europe has strong clinical adoption but greater price regulation and earlier generic pressure. Japan and other developed Asian markets provide additional volume but lower pricing than the United States.
Emerging markets offer volume growth but are more exposed to local generic manufacturers, tender procurement, lower reimbursement, and reduced branded pricing. Manufacturing and supply-chain barriers are limited compared with biologics because both ingredients are small molecules. The principal barriers are regulatory approval, active-ingredient manufacturing quality, bioequivalence, intellectual property, and payer access.
Key Takeaways
- Empagliflozin has the stronger market outlook because it is used in diabetes, heart failure, and chronic kidney disease.
- Jardiance generated approximately $7.1 billion in reported revenue in 2023 and remained a major growth product in 2024.
- Linagliptin is a mature DPP-4 asset with value in renal impairment, older patients, and weight-neutral oral therapy.
- Glyxambi has strategic convenience value but faces substitution by separate tablets and generic components.
- U.S. generic risk is governed by Orange Book patents, Paragraph IV challenges, settlements, and possible section viii label carve-outs.
- Empagliflozin and linagliptin are small molecules and face generic, not biosimilar, competition.
- Jardiance’s post-exclusivity erosion may be moderated by cardiovascular and kidney-disease use, while Tradjenta is more exposed to rapid substitution.
- Boehringer Ingelheim and Eli Lilly have greater financial exposure to empagliflozin than to linagliptin.
FAQs About Empagliflozin and Linagliptin
Is empagliflozin more commercially valuable than linagliptin?
Yes. Empagliflozin has broader indications, stronger guideline support, higher reported revenue, and greater use outside diabetes.
Can linagliptin be used with empagliflozin?
Yes. The combination is marketed as Glyxambi, and the two ingredients can also be prescribed separately when clinically appropriate.
Will generic empagliflozin eliminate Jardiance revenue immediately?
No. Revenue generally declines in stages. The rate depends on the number of approved entrants, payer substitution, authorized generic strategy, and continued branded use in heart failure and chronic kidney disease.
Are there biosimilars for Jardiance or Tradjenta?
No. Both are small-molecule drugs. Competitors enter through the generic ANDA pathway rather than the biosimilar pathway.
Why does linagliptin remain relevant despite SGLT2 competition?
Linagliptin remains useful for patients who need oral, weight-neutral glucose lowering with low hypoglycemia risk and no renal dose adjustment.
References
- Eli Lilly and Company. (2024). 2023 annual report.
- Boehringer Ingelheim. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Jardiance prescribing information.
- The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388, 117-127.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
